HRP20161354T1 - Argininske soli agonista tlr7 - Google Patents

Argininske soli agonista tlr7 Download PDF

Info

Publication number
HRP20161354T1
HRP20161354T1 HRP20161354TT HRP20161354T HRP20161354T1 HR P20161354 T1 HRP20161354 T1 HR P20161354T1 HR P20161354T T HRP20161354T T HR P20161354TT HR P20161354 T HRP20161354 T HR P20161354T HR P20161354 T1 HRP20161354 T1 HR P20161354T1
Authority
HR
Croatia
Prior art keywords
salt
ethoxy
arginine
phosphonoethoxy
naphthyridin
Prior art date
Application number
HRP20161354TT
Other languages
English (en)
Croatian (hr)
Inventor
Stephanie Kay Dodd
Siddartha JAIN
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of HRP20161354T1 publication Critical patent/HRP20161354T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
HRP20161354TT 2012-03-07 2013-03-07 Argininske soli agonista tlr7 HRP20161354T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261608011P 2012-03-07 2012-03-07
EP13708142.8A EP2822947B1 (en) 2012-03-07 2013-03-07 Arginine salts of a tlr7 agonist
PCT/EP2013/054548 WO2013131985A1 (en) 2012-03-07 2013-03-07 Immunologically useful arginine salts

Publications (1)

Publication Number Publication Date
HRP20161354T1 true HRP20161354T1 (hr) 2016-12-02

Family

ID=47843276

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161354TT HRP20161354T1 (hr) 2012-03-07 2013-03-07 Argininske soli agonista tlr7

Country Status (18)

Country Link
US (1) US9320748B2 (https=)
EP (1) EP2822947B1 (https=)
JP (1) JP6325986B2 (https=)
CN (1) CN104203946B (https=)
AU (1) AU2013229466A1 (https=)
CA (1) CA2865759C (https=)
CY (1) CY1118091T1 (https=)
DK (1) DK2822947T3 (https=)
ES (1) ES2597755T3 (https=)
HR (1) HRP20161354T1 (https=)
HU (1) HUE030175T2 (https=)
LT (1) LT2822947T (https=)
MX (1) MX346678B (https=)
PL (1) PL2822947T3 (https=)
PT (1) PT2822947T (https=)
RU (1) RU2014140336A (https=)
SI (1) SI2822947T1 (https=)
WO (1) WO2013131985A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
AU2011295853A1 (en) 2010-09-01 2013-04-04 Irm Llc Adsorption of immunopotentiators to insoluble metal salts
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
MX372965B (es) 2012-03-08 2020-04-01 Glaxosmithkline Biologicals Sa Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
CN106103469B (zh) 2014-03-26 2020-11-27 葛兰素史密丝克莱恩生物有限公司 突变型葡萄球菌抗原
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
WO2021178306A1 (en) * 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
US20220280482A1 (en) * 2021-03-06 2022-09-08 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
DE69333110T2 (de) 1992-03-02 2004-05-06 Chiron S.P.A. Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
JPH10502366A (ja) 1994-07-01 1998-03-03 リカン・リミテッド ヘリコバクター・ピロリ抗原タンパク質調製品およびイムノアッセイ
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
JP2004502415A (ja) 2000-07-03 2004-01-29 カイロン エセ.ピー.アー. Chlamydiapneumoniaeに対する免疫化
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
RU2331435C2 (ru) 2001-12-12 2008-08-20 Чирон Срл. Иммунизация против chlamydia trachomatis
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
MXPA05013260A (es) 2003-06-26 2006-03-09 Chiron Corp Composiciones inmunogenicas para chlamydia trachomatis.
BRPI0508365A (pt) 2004-03-02 2007-07-24 Chiron Corp composições imunogênicas para chlamydia pneumoniae
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド 尿路病原性菌株由来の抗原
RU2007146137A (ru) 2005-05-12 2009-06-27 Новартис Вэксинес Энд Дайэгностикс, Инк. (Us) Иммуногенные композиции на основе chlamydia trachomatis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
CA2633142A1 (en) 2005-12-22 2007-10-04 Novartis Vaccines And Diagnostics, S.R.L. Chlamydial antigens
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
BR122016015627A2 (pt) 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
EP3263128A3 (en) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
ES2531115T3 (es) 2009-06-01 2015-03-10 Novartis Ag Combinaciones de clados de RrgB neumocócicos
JP5867952B2 (ja) * 2009-06-10 2016-02-24 ノバルティス アーゲー ベンゾナフチリジン含有ワクチン
CN102596240B (zh) 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
JO3257B1 (ar) * 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
WO2011027222A2 (en) * 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
AU2011295853A1 (en) 2010-09-01 2013-04-04 Irm Llc Adsorption of immunopotentiators to insoluble metal salts
EP2667852B1 (en) 2011-01-27 2016-11-09 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with crystallisation inhibitors
RU2014112343A (ru) * 2011-09-01 2015-10-10 Новартис Аг Оставы антигенов staphylococcus aureus, содержащие адъюванты

Also Published As

Publication number Publication date
CA2865759C (en) 2020-07-21
RU2014140336A (ru) 2016-04-27
EP2822947B1 (en) 2016-08-03
CN104203946A (zh) 2014-12-10
HUE030175T2 (en) 2017-04-28
WO2013131985A1 (en) 2013-09-12
SI2822947T1 (sl) 2016-10-28
JP2015511957A (ja) 2015-04-23
JP6325986B2 (ja) 2018-05-16
CN104203946B (zh) 2017-03-22
PL2822947T3 (pl) 2017-01-31
MX2014010423A (es) 2014-09-22
DK2822947T3 (en) 2016-09-19
US9320748B2 (en) 2016-04-26
MX346678B (es) 2017-03-29
ES2597755T3 (es) 2017-01-20
EP2822947A1 (en) 2015-01-14
CA2865759A1 (en) 2013-09-12
US20150125475A1 (en) 2015-05-07
CY1118091T1 (el) 2017-06-28
AU2013229466A1 (en) 2014-09-04
LT2822947T (lt) 2016-10-10
PT2822947T (pt) 2016-09-26

Similar Documents

Publication Publication Date Title
HRP20161354T1 (hr) Argininske soli agonista tlr7
JP2015511957A5 (https=)
BR112013010167A2 (pt) sais de dimetilamida do ácido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-ilamino)-7h-pirrol[2,3-d]pirimidino-6-carboxílico e processos para sua produção
HRP20210529T1 (hr) Inhibitori za mk2 i njihove uporabe
JP2013523560A5 (https=)
EP3421468A3 (en) Methods of preparing inhibitors of influenza viruses replication
JP2014517907A5 (https=)
RU2013139873A (ru) Опорные отметки для идентификации точки начала в системах определения оптической формы
JP2014525429A5 (https=)
WO2011143576A3 (en) System and method for robust calibration between a machine vision system and a robot
JP2014218522A5 (https=)
SMT202000248T1 (it) Derivati di estere di acido boronico ciclico e relativi usi terapeutici
SG10201500639TA (en) Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
EP2718265A4 (en) PROCESS FOR THE PREPARATION OF [(3-HYDROXYPYRIDINE-2-CARBONYL-) AMINO-] ALKANIC ACIDS, ETHERS AND AMMUNES
IL285262A (en) Process for the preparation of fulvestrant 3-boronic acid
EP2822972A4 (en) IMPROVED METHOD FOR THE PRODUCTION OF A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX
EP2621284A4 (en) Method for preparation of an aqueous glyphosate concentrate
WO2015011119A3 (en) Salts of dasatinib in amorphous form
CA2899024C (en) Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
FR2964968B1 (fr) Procede de preparation d?un complexe d?acide et d?un metal
GB201319166D0 (en) Process for the preparation of herbicidal carboxylic acid salts
CR20140462A (es) Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil]etil} amino) -1-hidroxietil]-8-hidroquinolin-2(1h)-ona
FR2961507B1 (fr) Procede de preparation d'acroleine a partir de glycerol ou de glycerine
FR2999086B1 (fr) Composition orale et/ou buccale sous forme de film fin d'un principe actif faiblement soluble, son procede de preparation et son utilisation
FR3053336B1 (fr) Procede de preparation de l'acide 2,5-furane dicarboxylique (fdca) a partir de derives de pentoses